{
    "2019-01-31": [
        [
            {
                "time": "2019-01-31",
                "original_text": "Nasdaq Closes Out Best Month Since 2011",
                "features": {
                    "keywords": [
                        "Nasdaq",
                        "Best Month",
                        "2011"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "technology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-01-31",
                "original_text": "Merck's Pneumococcal Vaccine Gets Breakthrough Therapy Status",
                "features": {
                    "keywords": [
                        "Merck",
                        "Pneumococcal Vaccine",
                        "Breakthrough Therapy"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-01-31",
                "original_text": "Dow Movers: DWDP, PFE",
                "features": {
                    "keywords": [
                        "Dow",
                        "DWDP",
                        "PFE"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "industrial",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-01-31",
                "original_text": "Pfizer Stock’s ‘Dark Period’ Might Finally Be Over",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Dark Period",
                        "Over"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-01-31",
                "original_text": "Pfizer: Ibrance and Xtandi Are Key Oncology Assets",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Ibrance",
                        "Xtandi",
                        "Oncology"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-01-31",
                "original_text": "Pfizer Rises 3%",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Rises",
                        "3%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-01-31",
                "original_text": "Health Care Sector Update for 01/31/2019: SCYX, PULM, BAX, JNJ, PFE, ABT, MRK, AMGN",
                "features": {
                    "keywords": [
                        "Health Care",
                        "Sector Update",
                        "SCYX",
                        "PULM",
                        "BAX",
                        "JNJ",
                        "PFE",
                        "ABT",
                        "MRK",
                        "AMGN"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-01-31",
                "original_text": "Oncology Portfolio: Pfizer’s Key Growth Driver in Fiscal 2018",
                "features": {
                    "keywords": [
                        "Oncology",
                        "Pfizer",
                        "Growth Driver",
                        "Fiscal 2018"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-01-31",
                "original_text": "See what the IHS Markit Score report has to say about Pfizer Inc.",
                "features": {
                    "keywords": [
                        "IHS Markit Score",
                        "Pfizer"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-01-31",
                "original_text": "Pfizer’s Expenses Are Expected to Rise in Fiscal 2019",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Expenses",
                        "Expected",
                        "Rise",
                        "Fiscal 2019"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-01-31",
                "original_text": "Why are deep-pocketed biotechs cutting hundreds of jobs?",
                "features": {
                    "keywords": [
                        "deep-pocketed biotechs",
                        "cutting",
                        "jobs"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-01-31",
                "original_text": "What Should Apple Do With Its Cash?",
                "features": {
                    "keywords": [
                        "Apple",
                        "Cash"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-01-31",
                "original_text": "Jim Cramer: When Is a Miss Not a Miss?",
                "features": {
                    "keywords": [
                        "Jim Cramer",
                        "Miss"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general market"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}